Immunis has reported interim Phase 2 clinical data showing improvements in physical function among...
NEWS
Wave Life Sciences 2026 strategic priorities accelerate WVE-007...
Wave Life Sciences 2026 strategic priorities were outlined by the company at the 44th Annual J.P...
Novartis ianalumab receives FDA Breakthrough Therapy designation...
Novartis has received US Food and Drug Administration Breakthrough Therapy designation for...
Agentic AI gap highlighted across life sciences and pharma...
Life sciences and pharmaceutical organisations report a growing gap between their ambitions for...

